Cart
sales@molnova.com
Methyl 4-hydroxycinnamate (b)
CAS No. 19367-38-5
Methyl 4-hydroxycinnamate (b)( pCAME | p-CAME | p CAME )
Catalog No. M18184 CAS No. 19367-38-5
Methyl trans-p-Coumarat is a predicted metabolite generated by BioTransformer1 that is produced by the metabolism of methyl 3-phenylprop-2-enoate.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 38 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMethyl 4-hydroxycinnamate (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyl trans-p-Coumarat is a predicted metabolite generated by BioTransformer1 that is produced by the metabolism of methyl 3-phenylprop-2-enoate.
-
DescriptionpCAME is an inducer of ectopic tail formation of zebrafish.
-
In Vitro——
-
In Vivo——
-
SynonymspCAME | p-CAME | p CAME
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number19367-38-5
-
Formula Weight178.18
-
Molecular FormulaC10H10O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (561.23 mM)
-
SMILESCOC(=O)/C=C/c1ccc(cc1)O
-
Chemical Name3-(4-Hydroxy-phenyl)-acrylic acid methyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
OR-1896
OR-1896 is the active metabolite of Levosimendan, a highly specific phosphodiesterase (PDE III) inhibitor, a vasodilator with partial anti-inflammatory properties that produces vasodilation in different types of blood vessels through activation of ATP-sensitive (KATP) and other potassium channels.
-
CHET3
CHET3 is a highly selective allosteric activator for TASK-3-containing K2P channels. CHET3 has shown potent in vivo analgesic effects in various acute and chronic pain models in rodents.
-
TKIM
TKIM is a TWIK-related potassium channel 1 (TREK-1) inhibitor, binding to the pocket of the intermediate (IM) state of TREK-1.TKIM binds to the pocket of the IM state of TREK-1, which differs from the binding of common inhibitors, which bind to channels in the inactive state.?
